MPIP: Melanoma Patients Information Page

The MPIP is the oldest and largest community of people affected by melanoma hosted through the Melanoma Research Foundation. It is designed to provide support and information to caregivers, patients, family and friends. Once you have been touched by melanoma—either as a patient or as a family member or friend of a patient—you become part of a community. It is not a community anyone joins willingly. But if you must be part of this group, you will find no better place to find the tools you need in your journey with this cancer, and the friends who can make that journey more bearable.

The information on the bulletin board is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.

Expand/ Collapse Topic
Replies By
View Topic
NYKaren's picture
Replies 11
Last reply 9/13/2011 - 9:32pm

Hi everyone,

came to Yale yesterday.  they do 2 bags a day.  had 1st last nite, second this a.m, 3rd in about 20 min.

everyone is great here.  It' defintely NOT NEW YORK.  (although there are some advantages to NY, epecially if you eat a kosher diet.  LOL.)  losing appetite anyway, always PB & bananas.

no side efffects to speak of till this afternoon.  Red rash on chest without itching, lower urine output (but I amazed them at how much I was putting out--lots of water,  low fever & flu-like symptoms.  Was shocked that I havenn't gotten the tremors, but we'll see what tonite brings.

I know I'll feel progressively worse, MIGHT post  in coming days, will definately do so after return Sun. or Mon.

You guys are great.

 take care,


Don't Stop Believing

Login or register to post replies.

JerryfromFauq's picture
Replies 22
Last reply 9/13/2011 - 4:50pm

I have been asked about an update by so many people that I will post here even if this is not a totally melanoma related item.  Life does go on!  Look for the good things and don;t just concentrt on what MIGHT happen.

   My fifthteenth Grandchild (9th Grandson) Has deided to make his arrival.  My daughter said that it was an easy 19 hours (of the 21 hours) of labor.    Uriah Ellis Haessly  arrived at 01:41 am 8/7/2011.  He is 7 lbs 7.8 oz and is 19 1/4 inches long.

I'm me, not a statistic. Praying to not be one for years yet.

Login or register to post replies.

Lisa13's picture
Replies 5
Last reply 9/13/2011 - 3:11pm

I'm 9 days out from my second infusion of Yervoy and havn't experienced any side effects. However, within the past couple of days, I've been feeling fatigued which is quite out of character for me. I just finished moving house and thought I was tired as a result of moving, but I find myself wanting to sleep in more in the morning and get tired in the afternoon. After reading my clinical trial notes, fatigues/tiredness is an autoimmune response, so at least something is starting to happen.

On another note, my hair is VERY dry!  I wish the very best for everyone in this battle.

Lisa - Stage 4

Many impossible things have been accomplished for those who refuse to quit

Login or register to post replies.

Impression: Many of the subcentimeter hepatic lesions are smaller or absent compared to previous.  The largest hepatic lesion (1.3 x 0.9cm) and enlarged lymph nodes (3.2 x 1.7cm and 1.8 x 0.8cm) within the left inguinal and obturator regions are unchanged.  Bony metastases unchanged.


I should be thrilled but for some odd reason I am disappointed?  Dr. had suggested I might be in remission at this scan so I feel I let myself and my family down?  I wish I understand this reaction because it makes NO sense.

Doing nothing for now.  Next scan in 3mos. ( May start Yervoy at that time).  One of my questions long does IL2 treatment boost the immune system to keep working?  (hopefully that made sense)  First scan after treatment was kicking mel's it seems to have stalled?  Maybe I just don't understand this disease very well.  Do any of you have anything of offer my thought process that maybe I am missing?

Lytic disease...can this condition eventually heal itself?  The residual pain (compared to previous pain) is totally livable but my mind wants to believe pain = active melanoma. 

Thank you in advance for any replies.  I am just recently able to do some research and it can be so confusing and overwhelming!


Login or register to post replies.

bs010kbb's picture
Replies 7
Last reply 9/13/2011 - 2:00pm

I have completed all tests and received the clearance to participate in the trial viewing Interferon vs. Yervoy in an adjuvant therapy trial. I am 12 weeks post surgery and will begin treatment tomorrow. While I have commented on some postings, I have not posted since my initial diagnosis early July - what a wonderful, supportive group to be a part of. I was hoping to receive Yervoy in the trial but I was selected through radomization to receive Interferon. I am aware of all the side effects but if anyone has any recommendations of items to bring with me for 'comfort measures' or perhaps items that I should make sure I have within the home, I would appreciate feedback. It is always nice to know the 'tricks' that worked for others to keep comfortable during this time.

I am hoping that the side effects are minimal as the M4M Walk in our area is scheduled for the 18th of September. I will have 40+ family members/friends walking with me that day and we have raised over $8500 to date and keep going!!

Blessings to everyone -


Login or register to post replies.

Anonymous's picture
Replies 5
Last reply 9/12/2011 - 8:24pm
Replies by: Anonymous, JerryfromFauq, mother-to-be

Anyone know how Michelle is doing. I hope that things are going well for her & the baby.

Login or register to post replies.

renakimu's picture
Replies 6
Last reply 9/12/2011 - 7:17pm

hello everyone!!

once again i have to say that saring with you things is very important for me!now i dont have smth to sare but i have smthg to ask.i have told you that my mum is 3b stage from april from a mole in her back, iwanted to have your personal expeerience with reoccurance, most of all the time that the beast came back...i know that every person is completely different from an other but just wanted to see....i am very thakefull to all of you..


best wished and many years of "NED" to all from my heart


Login or register to post replies.

arborbnb's picture
Replies 7
Last reply 9/12/2011 - 6:09pm
Replies by: bcl, arborbnb, Donna M.

September 11, 2001 was a very strange day in our house.  the world was in chaos with the news of the Twin Towers.  In our house there was joy because my husband Peter, who was newly diagnosed Stage 3 had his scans and we got the call in the afternoon they were clear!!!!


Now ... 10 years later after IFN, surgeries and radiation we  rejoice in our good luck.


Keep up the fight .... Peter was one of the "responders" to IFN and although they never say he is cured, he has seen two grandchildren born, returned to work, tries to swim a kilometer 3 times a week ( in spite of an axillary node dissection and nasty radiation burns) .........


There is hope.  Now we are dealing with a daughter with a diffuse astrocytoma.  Treatment for this disease is in the dark ages and difficult and very wait and seel.  The prognosis long term is not good.


Julie in Prince George, BC Canada

Login or register to post replies.

JerryfromFauq's picture
Replies 2
Last reply 9/12/2011 - 5:05pm
Replies by: jax2007gxp, bcl

Trial Assesses SLNB's Future in Melanoma Management
Elsevier Global Medical News. 2011 Sept 7, ML Zoler

NEW YORK (EGMN) - Sentinel lymph node biopsy continues to aid the management of about 30% of melanoma patients, though its role in the future will depend on ongoing follow-up of a major trial that started nearly 20 years ago to assess the effect of SLNB on patient survival.

But SLNB's role could soon be upstaged by molecular profiling and the identification of specific genetic mutations that drive various melanoma subtypes, Dr. Timothy M. Johnson said at the American Academy of Dermatology's Summer Academy Meeting.

"In the future, I hope we can do molecular profiling on melanoma and [based on that] tell patients who will benefit [from various targeted treatments] and who won't. We are already doing this [on an investigational basis] with several new molecular profiling tests such as BRAF mutations" and treatment with vemurafenib, said Dr. Johnson, a professor of dermatology at the University of Michigan in Ann Arbor.

For the time being, melanoma patients should be counseled regarding SLNB if their tumors are at least 0.75 mm in Breslow depth and if they meet certain other criteria.

Even patients with thinner tumors should be counseled on the pros and cons of SLNB, because they will likely hear or know about the technique and may have questions. That is the approach taken at the University of Michigan and other centers, he said.

"SLN status is a powerful predictor of survival in the relatively small subset of patients where SLNB is indicated," he said. Reasons not to do SLNB include thin primary melanomas generally less than 0.75 mm with a low probability of a positive SLNB, high comorbidities, and maybe prior wide local excision, certainly in areas of ambiguous lymphatic drainage or following a local flap. This group includes about 70% of all U.S. melanoma patients. Albeit rarely, these thin lesions may be at higher risk when they have greater degrees of adverse features or positive deep margins on shave biopsy.

Melanoma patients with primary tumors that are 0.75-0.99 mm generally need an additional risk factor, such as ulceration, young age - up to about 40 years old, an increased mitotic rate, or angiolymphatic invasion to justify SLNB. When patients have additional risk factors, "we have a discussion with the patient to help them decide," he said. "We tell them the likely rate of positive lymph nodes based on our best information."

A clearer role for SLNB exists for patients with tumors with a Breslow thickness of 1 mm or greater. In these patients, exclusions from SLNB include "highly significant" medical comorbidities, a prior wide excision of the tumor, and tumors in "ambiguous" lymphatic drainage areas, such as the central back or central chest. Even in these cases, exclusion from SLNB "usually occurs but not always," Dr. Johnson noted.

Patients whose tumors have a Breslow thickness of more than 4 mm are also candidates for SLNB. In these cases, SLNB can help refine the patient's prognosis, and may also aid the choice of adjuvant therapy.

Historically, patients with tumors 4 mm or larger were considered likely to have distant metastatic disease and a poor prognosis, and, hence, no benefit from SLNB. But Dr. Johnson and his colleagues showed a substantial difference in survival rate between patients with positive and negative SLNs even when they had thicker primary tumors.

In a series of 227 patients with melanomas at least 4 mm thick and no clinically or radiologically-apparent distant disease, patients with a positive SLNB had a 5-year overall survival rate of 47%, while patients with negative SLNs had a 5-year survival rate of 80%, a statistically significant difference (P less than .0001). The difference in 5-year distant disease-free survival rates ran slightly larger, 85% in the node-negative patients and 48% in the node-positive patients (P less than .0001) (Cancer 2009;115:5752-60). Following this study, supporting evidence has come from several other research groups.

The ongoing Multicenter Selective Lymphadenectomy Trial (MSLT) should provide more definitive evidence on the survival effects of SLNB. The interim, 5-year follow-up data from 1,327 patients at 18 worldwide centers reported in 2006 included patients with primary-tumor Breslow thicknesses of 1.2-3.5 mm. Although the study's primary endpoint of the 5-year melanoma-specific survival rate was similar in the patients randomized to SLNB or wide local excision (87%), the prespecified secondary endpoint of 5-year disease-free survival ran 78% in patients who underwent SLNB and 73% in the wide excision group, a statistically-significant difference (P = .009) (N. Engl. J. Med. 2006;355:1307-17).

"The question is, can we identify a subset of patients with occult nodal disease with SLNB, intervene early, and improve outcomes? At face value, the third interim analysis data [the 2006 report] suggests potentially yes. However, this is a subset analysis and its validity can be debated. The data certainly support the potential for a subset benefit in node-positive patients," said Dr. Johnson. Updated survival results from a longer-term, fourth interim analysis of the MSLT survival outcomes are expected within the next year, and will help answer this question.

In addition to the disease-free survival benefit shown in the MSLT, the 30% of melanoma patients who are candidates for SLNB stand to gain useful prognostic information from the procedure. On average, about 20% of patients who are eligible for SLNB have a positive SLN, and this subgroup of patients also stand to benefit from more durable regional control of their disease with better quality of life. The survival benefit most likely occurs in a subset, perhaps 20%, of the node-positive patients, he said.

In summary, Dr. Johnson said the main reasons to consider SLNB are prognosis, durable regional control, and potential survival benefit in a select subset. These factors should be presented in "an honest discussion with the patient and family about the risks and benefits of SLNB, to help them make a best informed decision," he said.

Although many cancer centers currently use SLNB for melanoma in the way outlined by Dr. Johnson, with "not much controversy" among the "mainstream" of physicians and surgeons who treat melanoma, he noted that "there is posturing and emotion with this procedure," with controversy among some clinicians about the proper role.

"Some dermatologists don't believe that SLNB should be used for anybody, and some surgeons overuse it on everybody. The answer [on when to use SLNB] is somewhere in between," he said in an interview. The forthcoming, longer-term follow-up data from MSLT may help clinicians how best to use SLNB most appropriately, he added.

Dr. Johnson said that he had no disclosures.

I'm me, not a statistic. Praying to not be one for years yet.

Login or register to post replies.

Anonymous's picture
Replies 1
Last reply 9/12/2011 - 1:59pm
Replies by: washoegal



I am coming up for an appt with Dr. O'day but told he is on leave of absence. Anyone know when he is coming back?



Login or register to post replies.

jmmm's picture
Replies 6
Last reply 9/12/2011 - 1:29pm
Replies by: rbruce, JerryfromFauq, Charlie S, Anonymous, MariaH

I'm looking for information on what other melanoma specialists are recommending right now.  My husband was dx with stage 4 in January.  He finished yervoy in July--2 tumors disappeard, but by the end of August, he now has 2 more tumors.  His doctor isn't a melanoma specialist--we have an appointment next week with one.  From the research we've done, we feel like there are 3 main options--Zelboraf, IL-2, and ACT trials.  We've found (from another patient), that John Hopkins recommends Zelboraf, following yervoy.  We're wondering what other specialists are suggesting now.  Thanks,

Login or register to post replies.

j.m.l.'s picture
Replies 2
Last reply 9/12/2011 - 12:27pm
Replies by: sss, JerryfromFauq

I expect to start a treatment this week for mel. recurring. Has anyone had experience w. zelboraf. I know its very new on market but has anyone started this drug. Any effects good or bad. Please help.

Login or register to post replies.

Gene_S's picture
Replies 0

Jan please let us know how

Dirk is doing when you get a chance.

Judy wife of Gene Stage IV -Oct.  2010

Live 4 today. Thank God for all he has done for us. Looking forward to enjoying tomorrow.

Login or register to post replies.

Lori C's picture
Replies 9
Last reply 9/10/2011 - 10:46pm

I hope this is okay.  Many of you "know' Shelly in Switzerland, the expat from Vermont who, with her family, had moved to Switzerland and had been fighting stage four melanoma.  Shelly's positive spirit always inspired me.  She passed away last week.  Here is her Caring Bridge site

Shelly had experienced good results with treatment, and had enjoyed what her husband called "the gift of extended life" as a result of it.  She was an amazing warrior.


Lori Challinor

Login or register to post replies.